1. A phase III, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab in patients with metastatic or recurrent nonsquamous non-small cell lung cancer. (August 2020) Authors: Reck, Martin; Luft, Alexander; Bondarenko, Igor; Shevnia, Serhii; Trukhin, Dmytro; Kovalenko, Nadezhda V.; Vacharadze, Kakha; Andrea, Fülöp; Hontsa, Anatoliy; Choi, Jihye; Shin, Donghoon Journal: Lung cancer Issue: Volume 146(2020) Page Start: 12 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Issue 10308 (9th October 2021) Authors: Felip, Enriqueta; Altorki, Nasser; Zhou, Caicun; Csőszi, Tibor; Vynnychenko, Ihor; Goloborodko, Oleksandr; Luft, Alexander; Akopov, Andrey; Martinez-Marti, Alex; Kenmotsu, Hirotsugu; Chen, Yuh-Min; Chella, Antonio; Sugawara, Shunichi; Voong, David; Wu, Fan; Yi, Jing; Deng, Yu; McCleland, Mark; Be... Journal: Lancet Issue: Volume 398:Issue 10308(2021) Page Start: 1344 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel. Issue 2 (November 2015) Authors: Reck, Martin; Mellemgaard, Anders; von Pawel, Joachim; Gottfried, Maya; Bondarenko, Igor; Cheng, Ying; Zarogoulidis, Kostas; Luft, Alexander; Bennouna, Jaafar; Barrueco, José; Aboshady, Hesham; Hocke, Julia; Kaiser, Rolf; Douillard, Jean-Yves Journal: Lung cancer Issue: Volume 90:Issue 2(2015:Nov.) Page Start: 267 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Issue 10212 (23rd November 2019) Authors: Paz-Ares, Luis; Dvorkin, Mikhail; Chen, Yuanbin; Reinmuth, Niels; Hotta, Katsuyuki; Trukhin, Dmytro; Statsenko, Galina; Hochmair, Maximilian J; Özgüroğlu, Mustafa; Ji, Jun Ho; Voitko, Oleksandr; Poltoratskiy, Artem; Ponce, Santiago; Verderame, Francesco; Havel, Libor; Bondarenko, Igor; Kazarnowic... Journal: Lancet Issue: Volume 394:Issue 10212(2019) Page Start: 1929 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study. Issue 6 (20th February 2023) Authors: Johnson, Melissa L.; Cho, Byoung Chul; Luft, Alexander; Alatorre-Alexander, Jorge; Geater, Sarayut Lucien; Laktionov, Konstantin; Kim, Sang-We; Ursol, Grygorii; Hussein, Maen; Lim, Farah Louise; Yang, Cheng-Ta; Araujo, Luiz Henrique; Saito, Haruhiro; Reinmuth, Niels; Shi, Xiaojin; Poole, Lynne; P... Journal: Journal of clinical oncology Issue: Volume 41:Issue 6(2023) Page Start: 1213 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Issue 1 (January 2021) Authors: Goldman, Jonathan W; Dvorkin, Mikhail; Chen, Yuanbin; Reinmuth, Niels; Hotta, Katsuyuki; Trukhin, Dmytro; Statsenko, Galina; Hochmair, Maximilian J; Özgüroğlu, Mustafa; Ji, Jun Ho; Garassino, Marina Chiara; Voitko, Oleksandr; Poltoratskiy, Artem; Ponce, Santiago; Verderame, Francesco; Havel, Libo... Journal: Lancet oncology Issue: Volume 22:Issue 1(2021) Page Start: 51 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078). (February 2021) Authors: Lu, Shun; Wang, Jie; Cheng, Ying; Mok, Tony; Chang, Jianhua; Zhang, Li; Feng, Jifeng; Tu, Hai-Yan; Wu, Lin; Zhang, Yiping; Luft, Alexander; Zhou, Jian-ying; Ma, Zhiyong; Lu, You; Hu, Chengping; Shi, Yuankai; Ying, Kejing; Zhong, Hua; Poddubskaya, Elena; Soo, Ross A Journal: Lung cancer Issue: Volume 152(2021) Page Start: 7 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Phase III double-blind study comparing the efficacy and safety of proposed biosimilar MYL-1402O and reference bevacizumab in stage IV non-small-cell lung cancer. (November 2021) Authors: Socinski, Mark A.; Waller, Cornelius F.; Idris, Tazeen; Bondarenko, Igor; Luft, Alexander; Beckmann, Katrin; Vishweswaramurthy, Ashwini; Loganathan, Subramanian; Donnelly, Charles; Hummel, Matthew A.; Shapiro, Roxann; Woods, Melody; Rao, Anita; Nayak, Vivek G; Ranganna, Gopinath; Barve, Abhijit Journal: Therapeutic advances in medical oncology Issue: Volume 13(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial. Issue 6 (June 2016) Authors: Reck, Martin; Socinski, Mark A.; Luft, Alexander; Szczęsna, Aleksandra; Dediu, Mircea; Ramlau, Rodryg; Losonczy, György; Molinier, Olivier; Schumann, Christian; Gralla, Richard J.; Bonomi, Philip; Brown, Jacqueline; Soldatenkova, Victoria; Chouaki, Nadia; Obasaju, Coleman; Peterson, Patrick; That... Journal: Journal of thoracic oncology Issue: Volume 11:Issue 6(2016) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer. (March 2022) Authors: Chang, Jianhua; Wu, Yi-Long; Lu, Shun; Wang, Jie; Mok, Tony; Zhang, Li; Feng, Jifeng; Wu, Lin; Tu, Hai-Yan; Zhang, Yiping; Luft, Alexander; Zhou, Jian-ying; Ma, Zhiyong; Lu, You; Hu, Chengping; Shi, Yuankai; Poddubskaya, Elena; Soo, Ross A.; Chia, Yee Hong; Penrod, John R. Journal: Lung cancer Issue: Volume 165(2022) Page Start: 71 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗